Back to News
Market Impact: 0.25
Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib
Source: Nasdaq
Regulation & LegislationHealthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Karyopharm Therapeutics submitted a supplemental NDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients. The company requested Priority Review, which could tighten the FDA timeline if granted. Overall, this is a positive regulatory step that may support investor sentiment for KPTI’s myelofibrosis program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
KPTI0.35
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Faraday Copper completes acquisition of BHP’s San Manuel project
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius